Our Vision
Deliver Precision Genetic Medicines to the Tissues That Need Them Most
The Dawn Platform
Two Complementary Platforms, One Precision Delivery Strategy.
Tissue-targeted system
Engineered delivery platforms for liver, CNS, and musculoskeletal applications, with tunable targeting and expression strategies designed to improve localisation and reduce off-target exposure.
Modality flexibility
Stealth lentiviral vectors and targeted lipid nanoparticle systems are selected based on disease biology, tissue access, and translational needs, supporting gene transfer, mRNA, siRNA, and other programmable nucleic acid payloads.
Modalities We Use
The right tool for each target.
LNP-based targeted delivery
Designed for tissue-targeted delivery of nucleic acid payloads, including mRNA and siRNA, where repeat dosing or modular payload adaptation may be advantageous. Dawn’s platform datasets support joint, cartilage, and BBB-relevant delivery performance in vivo.
Stealth Lentiviral Vector (sLV)
A third-generation in vivo lentiviral platform engineered with immune-evasion and tissue-restriction features for durable therapeutic expression. This platform underpins Dawn’s lead preclinical Hurler syndrome programme, DAWN-01.
Clinical Development Philosophy
Biomarker-anchored, safety-focused, and translationally disciplined
Dawn’s development strategy is designed to move programmes from preclinical proof-of-concept toward CTA/IND readiness through staged, evidence-led execution. We prioritise measurable biology, tissue-relevant endpoints, and early regulatory alignment to strengthen programme quality before first-in-human studies.
-
Rare Genetic Disorders (Brain and Bone):
Our first focus is severe rare genetic disease, where delivery barriers and multisystem pathology limit current treatment outcomes. Dawn’s lead preclinical Hurler syndrome programme, DAWN-01, is built on the stealth lentiviral platform and is supported by complementary targeted delivery datasets relevant to CNS and musculoskeletal tissues. This creates a strong translational foundation for future rare disease programmes.
-
Diseases with Unmet Medical Need:
Dawn also prioritises conditions with limited therapeutic options, especially where effective delivery into difficult tissues remains a core challenge. Our platform approach is designed to support expansion into neurological and musculoskeletal disorders where improved targeting may unlock new treatment strategies.
-
Enhancement of Existing Therapeutics:
Dawn’s delivery systems are designed to improve how nucleic acid therapies are distributed in the body by increasing tissue targeting and reducing non-productive exposure. This platform strategy can be adapted across multiple payload classes, including genes, mRNA, siRNA, and gene-editing components.
Data Science, AI & Analytics
Faster insights, smarter design
- Dawn Therapeutics is building an AI-enabled research platform to accelerate how we design, test, and refine targeted delivery systems. The platform supports early-stage scientific decision-making across RNA therapeutics and delivery engineering, helping our team prioritise the most promising constructs, formulations, and targeting strategies before moving into resource-intensive laboratory work. manufacturability.
- Our AI workflows are designed to support delivery system research at multiple levels, including payload design, targeting ligand selection, formulation optimisation, and tissue-delivery modelling. By integrating experimental data with computational modelling, the platform helps us improve design quality, reduce trial-and-error cycles, and make faster, evidence-based decisions as we advance programmes such as Hurler syndrome (MPS-1H).
Frequently Asked Questions (FAQ)
What makes Dawn’s delivery different?
Dawn combines two complementary delivery technologies: a stealth lentiviral platform for durable in vivo gene delivery and a targeted LNP platform for programmable nucleic acid payloads. Across these platforms, the design emphasis is tissue targeting, immune-risk reduction, and translational scalability.
Are Dawn’s programmes designed as one-time treatments?
Where disease biology supports durable expression, Dawn uses the sLV platform for one-time in vivo gene delivery strategies. For applications that may benefit from repeat dosing or payload flexibility, the targeted LNP platform provides an alternative development route.
How does Dawn approach access and scalability?
Dawn’s platform strategy is designed to address cost and manufacturing barriers early, with a focus on scalable processes and practical translational planning. In internal business planning, the company models lower-cost manufacturing pathways for targeted LNP products relative to conventional approaches, while maintaining a biomarker-led development strategy.
Are these therapies available to patients now?
No. Dawn’s programmes, including DAWN-01, are in preclinical development and are not approved for human use yet. The company is focused on building the preclinical, manufacturing, and regulatory package needed for future CTA/IND-ready programmes.
